Gene therapy regulation: could in-body editing fall through the net?
- PMID: 32214228
- PMCID: PMC7316830
- DOI: 10.1038/s41431-020-0607-y
Gene therapy regulation: could in-body editing fall through the net?
Abstract
Somatic gene therapies may be authorised for marketing in the EU under the advanced therapy medicinal product regulation. These therapeutic compounds are sufficiently novel and complex in their potential effects to require specialist evaluation. However, the current definition of gene therapy medicinal products ('GTMP') risks excluding molecules which are not manufactured through techniques involving recombination. We consider the way, in which the 'recombinant nucleic acid' aspect of the GTMP definition is challenged by developments in gene-editing technology, and why a broader scope of GTMP regulation may be desirable.
Conflict of interest statement
The authors declare that they have no conflict of interest.
References
-
- Council Regulation (EU) 536/2014 of 16 April 2014 on clinical trials on medicinal products for human use, and repealing Directive 2001/20/EC [2014] OJ L 158/1, Article 90. This reflects the prohibition in Article 13 Oviedo Convention, to which some EU Member States are party.
-
- Council Regulation (EC) 1394/2007 of 13 November 2007 on advanced therapy medicinal products and amending Directive 2001/83/EC and Regulation (EC) No 726/2004 [2007] OJ L324/121.
-
- European Medicines Agency, ʻScientific recommendation on classification of advanced therapy medicinal products EMA/814824/2018ʼ, 21 November 2018. https://www.ema.europa.eu/en/documents/report/scientific-recommendation-.... Accessed 17 March 2020.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
